Showing 2691-2700 of 3172 results for "".
- Mattel Releases New Barbie Dolls with Vitiligo, Alopeciahttps://practicaldermatology.com/news/mattel-releases-new-barbie-dolls-with-vitiligo-alopecia-1/2460268/In an effort to be more inclusive, Mattel, the maker of Barbie dolls, has released new dolls in its Fashionista line including a Barbie with alopecia and one with vitiligo. “For 2020, Barbie is continuing the journey to represent global diversity and inclusivity in the f
- Dominion Aesthetic Technologies, Inc.’s eon FR Scores FDA Nodhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-incs-eon-fr-scores-fda-nod/2460077/The FDA has cleared Dominion Aesthetic Technologies, Inc
- New Study Examines Safety and Efficacy of Higher Dose Botox Cosmetichttps://practicaldermatology.com/news/new-study-examines-safety-and-efficacy-of-higher-dose-botox-cosmetic/2457609/Allergan plc conducted a clinical trial to evaluate the duration of effect and safety of Botox Cosmetic 40, 60, and 80 unit doses versus Botox Cosmetic 20 unit dose in patients with moderate to severe glabellar lines. The primary efficacy endpoint was met and was statistically significant f
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- FDA Cracks Down on Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/fda-cracks-down-on-vaginal-rejuvenation/2457667/The FDA is cracking down on the use energy-based devices to perform vaginal 'rejuvenation.' The use of such devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontin
- Derm Brands Dove, Neutrogena, L'Oreal Among Top Skincare Social Influencershttps://practicaldermatology.com/news/derm-brands-dove-neutrogena-loreal-among-top-skincare-social-influencers/2457725/Engagement Labs’ TotalSocial® ranking of the top personal care and beauty brands in the US based on social influence show several popular dermatology brands in the Top 10, including Dove, Neutrogena, and L’Oreal. En
- White Coats, Scrubs Top Patient Preferences for Doctor's Attirehttps://practicaldermatology.com/news/white-coats-scrubs-top-patient-preferences-for-doctors-attire/2457735/What doctors wear matters…a lot, according to the largest-ever study of patient preferences for doctors’ attire. Just more than half of the 4,062 patients surveyed in the clinics and hospitals of ten major medical centers said that what physicians wear is important to th
- FDA: Pills Don't Replace Sunscreenhttps://practicaldermatology.com/news/fda-pills-dont-replace-sunscreen/2457749/The U.S. Food and Drug Administration (FDA) is cracking down on companies marketing supplements that claim to counter the effects of the sun's ultraviolet rays. These companies — marketing products called
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep